# US 2026/0152805 A1 · Methods of treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0152805 A1
- Document ID: US20260152805A1
- Status: Published application
- Kind: A1
- Application number: 19/459,938
- Filed: 2026-01-26
- Published: 2026-06-04
- Earliest claimed: 2019-11-27
- Assignees: NantCell, Inc.
- Applicants: Nantcell, Inc.
- Inventors: Sadanand VODALA; Andrew NGUYEN; Charles Joseph VASKE; Shahrooz RABIZADEH
- Web page: https://patentgrep.com/patent/US20260152805A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 33/243: Platinum; Compounds thereof
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/2086: {IL-13 to IL-16}
- A61K 39/0011: {Cancer antigens}
- A61K 39/001164: {GTPases, e.g. Ras or Rho}
- A61K 39/00117: {Mucins, e.g. MUC-1}
- A61K 39/001182: {Carcinoembryonic antigen [CEA]}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Multimodal cancer immunotherapy is a combination of cancer immunotherapies used to treat cancer in patients. T cell receptor diversity is used as a component of a method to treat cancer involving cancer therapy, including multimodal cancer immunotherapy.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method of increasing T cell receptor (TCR) diversity in a patient having cancer, the method comprising administering a multimodal cancer immunotherapy to the patient, wherein the multimodal cancer immunotherapy comprises:
a. an NK cell selected from the group consisting of aNK, haNK, taNK, and t-haNK; and
b. two or more immunotherapies selected from the group consisting of a viral vector expressing an antigen, a yeast immunotherapy, an immune checkpoint inhibitor, and an IL-15 superagonist;
wherein the TCR diversity in blood from the patient increases at least three-fold between a first time point of the multimodal cancer immunotherapy and a second time point of the multimodal cancer immunotherapy at least two months after the first time point.

### Claim 21 (depends on 20)

The method of claim 20, wherein the viral vector expressing antigen is an adenovirus-5 (Ad5)-based adenovirus vector.

### Claim 22 (depends on 21)

The method of claim 21, wherein in the Ad5-based adenovirus vector is ETBX-011, ETBX-051, and/or ETBX-061.

### Claim 23 (depends on 20)

The method of claim 20, wherein the yeast immunotherapy is GI-4000, GI-6207, and/or GI-6301.

### Claim 24 (depends on 20)

The method of claim 20, wherein the immune checkpoint inhibitor is an anti-PD-L1 IgG1 monoclonal antibody and/or an anti-VEGF IgG1 monoclonal antibody.

### Claim 25 (depends on 20)

The method of claim 20, wherein the IL-15 superagonist is N-803.

### Claim 26 (depends on 20)

The method of claim 20, wherein the multimodal cancer immunotherapy further comprises an immunotherapy selected from the group consisting of aldoxorubicin, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, leucovorin, nab-paclitaxel and combinations thereof.

### Claim 27 (depends on 20)

The method of claim 20, wherein the cancer is selected from the group consisting of breast cancer, lung cancer, skin cancer, brain cancer, spinal cord cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck cancer, gall bladder cancer, ovarian cancer, urothelial cancer, and blood cancer.

### Claim 28 (depends on 20)

The method of claim 20, wherein the cancer is selected from the group consisting of triple negative breast cancer (TNBC), non-small-cell lung carcinoma (NSCLC), head & neck squamous cell carcinoma (HNSCC), pancreatic adenocarcinoma, chordoma, melanoma, Merkel cell carcinoma, non-Hodgkin lymphoma, acute myelogenous leukemia, myelodysplastic syndrome, neuroblastoma, and glioblastoma.

### Claim 29 (depends on 20)

The method of claim 20, wherein the TCR diversity increases at least 4 fold, 5 fold, 6 fold, 7 fold, 8 fold, 9 fold, 10 fold, 11 fold, 12 fold, 13 fold, 14 fold, or 15 fold between the first and second time points.

### Claim 30 (depends on 20)

The method of claim 20, wherein the TCR diversity is calculated as a Shannon Wiener diversity index.

### Claim 31 (depends on 20)

The method of claim 20, wherein the TCR diversity is calculated for CDR3 regions from TCR α/β chains.

### Claim 32 (depends on 20)

The method of claim 20, wherein the TCR diversity is calculated for RNA sequences encoding CDR3 regions from TCR α/β chains.
